Expression of cyclin D1, p21WAF1, p53 and Ki-67 in hepatocellular carcinoma: A pathological study

Medical Journal of Chinese People's Liberation Army

Volumn 39, Issue 1, 2014, Pages 20-24

  Wang, Yu Lan ^a   Du, Jing Li ^a   Shi, Huai Yin ^a   Guo, Ai Tao ^a   Wei, Li Xin ^a   Zhao, Jing Min ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BEIJING 302 HOSPITAL   (China)

Author keywords

Carcinoma; Cyclin D1; Cyclin dependent kinase inhibitor p21; Hepatocellular; Ki 67 antigen; Tumor suppressor protein p53

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; KI 67 ANTIGEN; PROTEIN P53;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 84940313426     PISSN: 05777402     EISSN: None     Source Type: Journal    
DOI: 10.11855/j.issn.0577-7402.2014.01.05     Document Type: Article

References (29)

1. Yuen MF, Hou JL, Chutaputti A, et al. Hepatocellular carcinoma in the Asia Pacific Region [J]. J Gastroenterol Hepatol, 2009, 24(3): 346-353.
2. Pang R, Tse E, Poon RT. Molecular pathways in hepatocellular carcinoma[J]. Cancer Lett, 2006, 240(2): 157-169.
3. Wang J, Zhao J, Chu ES, et al. Inhibitory role of Smad7 in hepatocarcinogenesis in mice and in vitro [J]. J Pathol, 2013, 230(4): 441-452.
4. Park YH, Shin HJ, Kim SU, et al. Inos promotes HBx-induced hepatocellular carcinoma via upregulation of JNK activation [J]. Biochem Biophys Res Commun, 2013, 435(2): 244-249.
5. Wang K, Lim HY, Shi S, et al. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma[J]. Hepatology, 2013, 58(2): 706-717.
6. Joo M, Kang YK, Kim MR, et al. CyclinD1 overexpression in hepatocellular carcinoma[J]. Liver, 2001, 21(4): 89-95.
7. Lamb R, Lehn S, Rogerson L, et al. Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity [J]. Cell Cycle, 2013, 12(15): 2384-2394.
8. Che Y, Ye F, Xu R, et al. Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma[J]. Am J Pathol, 2012, 180(5): 1798-1807.
9. Gartd AL, Radhakfishnan SK. Lost in transeription: p2l repression mechanisms, and consequences [J]. Cancer Res, 2005, 65(10): 3980-3985.
10. Katiyar S, Dash BC, Thakur V, et al. P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India[J]. Cancer, 2000, 88(7): 1565-1573.
11. Azechi H, Nishida N, Fukuda Y, et al. Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas[J]. Oncology, 2001, 60(4): 346-354.
12. Choi YL, Park SH, Jang J J, et al. Expression of the G1-S modulators in hepatitis B virus-related hepatocellular carcinoma and dysplastic nodule: association of cyclin D1 and p53 proteins with the progression of hepatocellular carcinoma [J]. J Korean Med Sci, 2001, 16(4): 424-432.
13. Somasundaram K, Zhang H, Zeng YX, et al. Arrest of the cell cycle by the tumor-suppressor BRCA1 requires the CDK- WAF1 inhibitor p21 WAF1 /CiP1[J]. Nature, 1997, 389(6647): 187-190.
14. Caffo O, Doglioni C, Veronese S, et al. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up[J]. Clin Cancer Res, 1996, 2(9): 1591-1599.
15. Thor AD, Liu S, Moore DH, et al. P(21WAF1/CIP1) expression in breast cancers: associations with p53 and outcome[J]. Breast Cancer Res Treat, 2000, 61 (1): 33-43.
16. Nemes JA, Nemes Z, Mrton J. P(21WAF1/CIP1) expression is a marker of poor prognosis in oral squamous cell carcinoma[J]. J Oral Pathol Med, 2005, 34(5): 274-279.
17. Mitomi H, Ohkura Y, Fukui N. P21/ CIP1 expression in colorectal carcinomas is related to Kras mutations and prognosis[J]. Eur J Gastroenterol Hepatol, 2007, 19(10): 883-889.
18. Domagala W, Welcker M, Chosia M, et al. P21/WAF1/Cip1 expression in invasive ductal breast carcinoma: relationship to p53, proliferation rate, and survival at 5 years [J]. Virchows Arch, 2001, 439(2): 132-140.
19. Primdahl H, von der Maase H, Sorensen FB, et al. Immunohistochemical study of the expression of cell cycle regulating proteins at different stages of bladder cancer[J]. J Cancer Res Clin Oncol, 2002, 128(6): 295-301.
20. Gohring UJ, Bersch A, Becker M, et al. P21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer [J]. J Clin Pathol, 2001, 54(11): 866-870.
21. Lipponen P, Aaltomaa S, Eskelinen M, et al. Expression of p21 (Waf1/Cip1) protein in transitional cell bladder tumors and its prognostic value [J]. Eur Urol, 1998, 34(3): 237-243.
22. Kao J, Chuah SK, Huang CC. P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection [J]. Liver Int, 2007, 27(6): 772-781.
23. Park YN, Chae KJ, Kwon KW. P53 and p21/WAF1in hepatitis B virus related hepatocarcinogenesis[J]. Hepatogastroenterology, 2003, 50(53): 1292-1296.
24. McClelland RA, Gee JM, O'Sullivan L, et al. P21 /WAF1 expression and endocrine response in breast cancer[J]. J Pathol, 1999, 188(2): 126-130.
25. Kobayashi S, Matsushita K, Saigo K, et al. P211 (WAF1/ CIP1) messenger RNA expression in hepatitis B, C virus-infected human hepatocellular carcinoma tissues[J]. Cancer, 2001, 91(11): 2096-2103.
26. Qin LF, Ng IO. Expression of p27 (KIP1) and p21 (WAF1/ CIP1) in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis [J]. Hum Pathol, 2001, 32(8): 778-784.
27. Bouchard MJ, Wang L, Schneider RJ. Activation of focal adhesion kirtase by hepatitis B virus HBx protein: multiple functions in viral replication [J]. J Virol, 2006, 80(9): 4406-4414.
28. Fujimoto Y, Hampton LL, Wirth PJ, et al. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China[J]. Cancer Res, 1994, 54 (1): 281-285.
29. Pellikainen MJ, Pekola TT, Ropponen KM, et al. P21/WAF1 expression in invasive breast cancer and it association with p53, AP-2, cell proliferation, and prognosis[J]. J Clin Pathol, 2003, 56(3): 214-220.